NEW YORK CITY, NY / ACCESS Newswire / May 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apple Inc. ("Apple" or "the Company") (NASDAQ:AAPL). Investors who purchased Apple securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AAPL.

NEW YORK CITY, NY / ACCESS Newswire / May 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.

NEW YORK CITY, NY / ACCESS Newswire / May 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Meta Platforms, Inc. ("Meta" or "the Company") (NASDAQ:META). Investors who purchased Meta securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/META.

NEW YORK CITY, NY / ACCESS Newswire / May 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ:CAPR). Investors who purchased Capricor securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CAPR.

NEW YORK CITY, NY / ACCESS Newswire / May 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GoHealth, Inc. ("GoHealth" or "the Company") (NASDAQ:GOCO). Investors who purchased GoHealth securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GOCO.

NEW YORK, NY / ACCESS Newswire / May 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PACS Group, Inc. ("PACS Group" or "the Company") (NYSE:PACS). Investors who purchased PACS Group securities prior to April 11, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PACS.

NEW YORK CITY, NY / ACCESS Newswire / May 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sun Communities, Inc. ("Sun Communities" or "the Company") (NYSE:SUI). Investors who purchased Sun Communities securities prior to February 28, 2019, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SUI.

NEW YORK, NY / ACCESS Newswire / May 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of DMC Global Inc. ("DMC Global" or "the Company") (NASDAQ:BOOM). Investors who purchased DMC Global securities prior to January 29, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BOOM.

TORONTO--(BUSINESS WIRE)---- $ONCO #Cboe--Cboe Canada is pleased to announce that Onco-Innovations Limited is available for trading under the ticker symbol ONCO.

Medicus Pharma (NASDAQ:MDCX) has received regulatory approval from the UAE Department of Health to begin a Phase 2 clinical trial evaluating its non-invasive therapy for basal cell carcinoma (BCC) of the skin. The study, designated SKNJCT-004, will enroll up to 36 patients across four medical centers in the UAE.

Neils Christensen has a diploma in journalism from Lethbridge College and has more than a decade of reporting experience working for news organizations throughout Canada. His experiences include covering territorial and federal politics in Nunavut, Canada.

TORONTO, May 22, 2025 (GLOBE NEWSWIRE) -- POET Technologies Inc. ("POET" or the "Corporation") (TSXV: PTK; NASDAQ: POET), the designer and developer of the POET Optical Interposer™, Photonic Integrated Circuits (PICs) and light sources for the data center, tele-communication and artificial intelligence markets, is pleased to announce that, further to its news release dated May 20, 2025, it has completed a non-brokered private placement with a single strategic investor pursuant to which the Corporation issued 6,000,000 common shares of the Corporation (the "Common Shares") and one common share purchase warrant of the Corporation (the "Warrant") exercisable until May 22, 2030, …

XLK rebounded strongly in 2025, fueled by robust AI demand, strong tech earnings, and easing trade tensions with China. Tech sector earnings growth exceeded expectations, with mega-cap names like NVIDIA, Microsoft, and Broadcom leading the charge. XLK offers diversified exposure to leading large-cap tech stocks, making it a top pick for high-risk-tolerant investors seeking strong returns.

Joint Stock Company Kaspi.kz offers exceptional GARP potential, trading at under 7x forward earnings with robust growth, a dominant fintech super-app, and a hefty dividend yield. Recent share price weakness is driven by temporary headwinds: Turkey expansion costs, Hepsiburada losses, and regulatory changes, but I think these are likely to fade in 2H 2025. Kaspi's business is well-diversified, showing rapid revenue growth and high user engagement, with significant expansion potential in Turkey's large, underpenetrated market.

uCloudlink Group (UCL 0.30%) reported fiscal 2025 first-quarter results on May 21, 2025, delivering $18.75 million in revenue, a 3.3% increase over the prior year period, and positive cash generation. The company advanced its portfolio with multiple new product launches across Internet of Things, pet, and fixed broadband segments.

CG Oncology stock surges 27% in a month following superior efficacy data from its phase III study of cretostimogene for a bladder cancer indication.

PepsiCo and Monster battle for energy drink supremacy. Is scale or specialization the winning formula?

Can tech-focused Hercules Capital outperform diversified Ares Capital in today's uncertain market? Let's find out.

Tesla (NASDAQ:TSLA) can be a pretty difficult Mag Seven stock to value, given all that hinges on robotaxis.

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.